Comparison of the Effects by Obybutynin and Tolterodine on Spina Bifida Patients: A Pilot Crossover Study
|
|
- Gwenda Miles
- 5 years ago
- Views:
Transcription
1 LUTS (2011) 3, ORIGINAL ARTICLE Comparison of the Effects by Obybutynin and Tolterodine on Spina Bifida Patients: A Pilot Crossover Study Akihiro KANEMATSU, 1,2 Kazuyoshi JOHNIN, 2,3 Koji YOSHIMURA, 1 Masaaki IMAMURA, 1 and Osamu OGAWA 1 1 Department of Urology, Kyoto University, Kyoto, Japan, 2 Urology Clinic, Shiga Medical Center for Children, Moriyama, Japan, and 3 Department of Urology, Shiga University of Medical Sciences, Otsu, Japan Objectives: To compare the effects of obybutynin and tolterodine in neurogenic bladder patients with spina bifida in a crossover study. Methods: Seven myelomeningocele and one spinal lipoma cases, maintained with obybutynin and clean intermittent catheterization for more than 60 months, were enrolled. Age ranged from 8 to 23 years (mean 12.0, male/ female = 2/6). After 2 weeks of washout period, obybutynin (0.3 mg/kg, maximum 12 mg) or tolterodine (0.12 mg/kg, maximum 4 mg) was administered for 4 weeks, and then switched to the other drug for 4 weeks. At the end of the three periods, the patients and/or parents documented urinary storage status and adverse effects, and urodynamic study was performed. Results: In seven cases undergoing sequential urodynamic study, the baseline compliance of the patients (6.81 ± 1.83) increased to 9.98 ± 4.97 by obybutynin and ± 2.53 by tolterodine (P < 0.05 for each). Better compliance was noted in two cases with tolterodine and in two cases with obybutynin. Stronger adverse effects were reported in three out of eight patients (37.5%) by obybutynin and three out of eight patients (37.5%) by tolterodine. Although storage effect and side effects were equivalent for total patients, markedly diverse response was noted for each patient, with five choosing tolterodine and three choosing obybutynin. Conclusions: Individualized evaluation is required for optimal choice of anticholinergics. Key words neurogenic bladder, obybutynin, spina bifida, tolterodine 1. INTRODUCTION Anticholinergic agents are first-line therapy for reduction of intravesical pressure in low-compliant neurogenic bladder (NGB) frequently seen in patients with spina bifida. 1,2 The drugs play a central role in modern management of NGB due to spina bifida. High dosage of anticholinergic agent reduces the contraction and tonus of the bladder smooth muscle by blockade of muscarinic receptors and achieves reduction of intravesical pressure, which is vital for preventing damage to the upper urinary tract. 2 The effect of the drug may not only be palliative, as early administration of anticholinergics reportedly improves the prognosis of bladder function itself, and may reduce the cases requiring bladder augmentation. 1,3,4 Obybutynin chloride (obybutynin) has long been a standard drug used for this purpose. New anticholinergics, such as tolterodine, 5 solifenacin 6 and imidafenacin 7 have been introduced for adult overactive bladder (OAB) and shown to have less adverse effects than obybutynin. However, their utility for severe congenital NGB is not established, as the application of the drug is mainly directed by physician s initiative. For example, Ellsworth and colleagues have conducted a dose escalation study of tolterodine for pediatric NGB population, and reported reliable decrease of compliance in most of their patients, without significant side effects. 8 However, no direct comparison has been reported between obybutynin and tolterodine, and there is as yet no consensus for choice of anticholinergic drug in spina bifida patients. Herein, we conducted a pilot study of crossover comparison between obybutynin and tolterodine in patients with NGB due to spina bifida. 2. METHODS Neurogenic bladder patients due to spina bifida maintained on clean intermittent catheterization and with obybutynin ( mg/kg maximum 12 mg) for more than 60 months, and those who were able to document their urinary storage status and adverse effects, were enrolled. Correspondence: Akihiro Kanematsu, MD, PhD, Department of Urology, Kyoto University, 54 Shogoin-Kawaracho, Sakyo, Kyoto, Japan. Tel: ; Fax: aqui@kuhp.kyoto-u.ac.jp Received 22 November 2010; revised 24 December 2010; accepted 5 January DOI: /j x
2 100 Akihiro Kanematsu et al. TABLE 1. Demographic and pre-study data Case number Age Gender Original disease Pre-study obybutynin administration (months) Max capa (ml) Baseline UDS data Max pressure (cmh 2 O) Compliance (ml/cmh 2 O) LPP (cmh 2 O) 1 7 M MMC F MMC F MMC F MMC > F MMC M MMC > F MMC F Spinal lipoma >80 Capa, capacity (ml); LPP, leak point pressure (cmh 2 O); MMC, myelomeningocele; UDS, urodynamic studies. The patients having undergone any reconstructive surgery of the urinary tract were excluded. Out of 70 spina bifida patients followed at Shiga Medical Center for Children and at Kyoto University, 11 cases met the criteria, with eight patients and/or their guardians submitting written informed consent (Table 1). After 2 weeks of washout period, obybutynin (0.3 mg/kg, maximum 12 mg/day) or tolterodine (0.12 mg/kg, maximum 4 mg/day) was administered for 4 weeks, and then switched to the other drug for 4 weeks as open-label drugs. 8,9 Each drug was administered in divided dosage twice a day. Four cases were administered obybutynin preceding tolterodine with the remaining four administered the reverse. The order of the drugs was alternately assigned to the enrolled patients. At the end of each point, the patient or guardian recorded frequency/void (catheterization)/leak chart (FVC) for 2 days simultaneously with the documentation of adverse effects. In seven patients, sequential urodynamic studies (UDS) were also performed at the same time. The first test was done as standard video urodynamics, and the other two tests were done with saline without fluoroscopy. The maximal volume infused in the initial urodynamics during washout period was defined either from sensation of fullness in the patients having bladder sensation, or from maximal catheterized urine volume in clean intermittent catheterization chart in the patients having no filling sensation. Maximal pressure was defined as the intravesical pressure at the Maximal Capacity. Under administration of either drug, the infusion was continued until the intravesical pressure reached the Maximal Pressure defined in the initial test. Evaluated parameters for storage effect were compliance in UDS, functional bladder capacity and maximal dry time, and a 40% or more increase compared to the other drug was considered superior. Statistical analysis was performed by Wilcoxon s signed-rank test, with P < 0.05 considered significant. 3. RESULTS The patients demographics are shown in Table 1. Mean age at the study was 12.0 years old. According to FVC, one patient reported superior storage status with tolterodine and one patient with obybutynin (Table 2). In seven cases undergoing sequential UDS, both drugs increased bladder compliance significantly. The baseline compliance of the patients (6.81 ± 1.83 ml/ cmh 2 O) increased to 9.98 ± 4.97 by obybutynin, and ± 2.53 by tolterodine (P < 0.05 for each, but no significant difference between the two drugs). Although the effect in total patients was equivalent between the two drugs, a markedly diverse response was noted in cystometric curves of individual case (Fig. 1). Superior bladder compliance compared to the other drug was noted in two cases with tolterodine and in two cases with obybutynin. Stronger adverse effects were reported in three out of eight patients (37.5%) by obybutynin (dry mouth, 3; flushing, 1), and three out of eight patients (37.5%) by tolterodine (dry mouth, 2; flushing, 1). Finally, occurrence of the adverse effects did not always correlate with stronger storage effect (seen in cases 1, 5 and 6 [Table 2]). Based on these findings five patients chose tolterodine and three patients chose to continue obybutynin. 4. DISCUSSION The present report focuses on the comparison of tolterodine and obybutynin for treating spina bifida patients, and reveals a remarkable individual variation in response to the drugs. A group of new anticholinergic drugs recently introduced into the market have proven efficacy for the adult OAB population, with generally less adverse effects than obybutynin. 5 7 However, for appropriate application of these new drugs for severe congenital spinal disorders like spina bifida, comparison should be made with obybutynin, the standard drug. The new anticholinergics are intended to be used for OAB but not for the most severe NGB, such as spina bifida, and pharmaceutical companies has not been enthusiastic for their usage in pediatric cases. 10,11 In these patients, anticholinergics reduce intravesical pressure and improve bladder compliance, presumably by directly acting onto the muscarinic receptors of the bladder smooth muscle, with a dosage far above the standard dosage set for treatment of non-neurogenic OAB. 8,9 Thus, usage of these new anticholinergics for low compliant NGB requires an independent investigation at higher dosage in comparison with obybutynin.
3 Anticholinergics for Spina Bifida Patients 101 TABLE 2. Summary of the results UDS (compliance [ml/cmh2o]) FVC (max dry time [h])/max capacity [ml]) Adverse effects Final choice of the drug Adverse effects total Storage effects total Dry mouth Flushing Order of administration Baseline Obybutynin Tolterodine Baseline Obybutynin Tolterodine Case number 1 T O /140 3/190 3/120 O > T O< T None O < T O 2 T O N.A./120 N.A./160 N.A/150 O = T O= T O> T O> T O 3 T O / /200 3 /240 O < T O< T None O< T T 4 O T >4/235 >4/248 >4/268 O < T None None None T 5 O T /160 >4/260 >4/410 O < T O> T None O > T T 6 O T >4/N.A. >4/N.A. >4/N.A. O > T None O< T O< T O 7 T O N.A. N.A. N.A./N.A. 30/ /416 O < T O> T None O> T T 8 O T >4/N.A. >4/500 >4/500 O = T O> T None O> T T O < T O > T The summary or the data shown in Fig % or more increase compared to the other drug. N.A., Data not available; O, obybutynin; T, tolterodine; UDS, urodynamic studies. The majority of the patients in this study were at high-risk for upper urinary tract damage and who might have required augmentation if anticholinergics failed. As their bladder function were maintained at stable status with high-dose obybutynin over long period, sequential comparison between tolterodine and obybutynin at high dosage was conducted in this study. Our study followed that of Ellsworth and colleagues, first reporting the efficacy of tolterodine for NGB due to spina bifida with escalated dosage. 8,12 The report has reasonably established a standard dosage of tolterodine for low-compliant bladders. The first finding in our study is that both tolterodine and obybutynin have significant and equivalent urinary storage effect overall according to UDS and FVC. However, the second, and the more important findings of this study, was that the effect of the drugs was not equivalent for each individual case. For example, superior bladder compliance in UDS compared to the other drug was noted in two cases with tolterodine and in two cases with oxybutynin (Fig. 1 and Table 2), and such differences were also reflected to clinical symptoms including functional bladder capacity and dry time. Such individual variability has also been encountered for adverse effects. Dry mouth, one of the typical adverse effects of anticholinergic, occurred in three out of eight patients; it was stronger for three obybutynin patients and two tolterodine patients. Although fewer side effects were initially expected for tolterodine from the data in adult OAB cases, the difference between obybutynin was not as dramatic as expected at the higher dosage required for NGB. While some patients definitively refused to resume obybutynin, some patients made the reverse decision and the number of choice was split for the two drugs (five for tolterodine and three for obybutynin). In these cases, the adverse effects may not simply imply elevated drug concentration, since stronger adverse effects were apparently uncorrelated with superior storage effect. The individual variability has been keynote findings of this study, and may denote heterogeneous nature of individual response to anticholinergics. Each cholinergic agent is known to have different affinity to muscarinic receptors of different organs. 5,13 A group reported that contraction of the bladder of spinal injury patients is different from normal bladder, in that the former was mediated by M2 muscarinic receptor, while the latter was mediated by M3 receptor. 13 Precise roles of M2 and M3 receptors for the effect of anticholinergicagentsinhealthy and diseased bladder are not completely elucidated yet. The anticholinergics may not only be a palliative measure to reduce intravesical pressure, but also have a protective effect against abnormal muscle remodeling in spina bifida patients. 1,3,4 As long as we do not fully understand the distinct role of cholinergics on bladder function, we may not be able to predict effects of each anticholinergic drug on each pediatric NGB. In addition, pharmacokinetics of each drug may further influence the effects. Consequently, each NGB patient responds differently to each anticholinergic drug, making an individualized approach mandatory for the choice of optimal drug. Further, we
4 102 Akihiro Kanematsu et al. Fig. 1 Overlapped cystometric curves at the three stages of the study. Cases 1 and 6 showed superior increase of compliance by obybutynin. Cases 4 and 5 showed superior increase of compliance by tolterodine. Cases 2, 3 and 8 showed equivalent effects. should note the mental disturbance caused by obybutynin due to the passage of the drug through the blood-brain barrier. 14,15 In this study no marked difference in mental activity was noted in the enrolled patients. As a limitation of the present study, the number of patients examined was too small to conclude the difference between the two drugs in the overall population, but rather the effect and adverse effect were just as equivalent between the two drugs. However, the response of individual cases in this report clearly indicates that, sideto-side comparison should be applied to any NGB case maintained with an anticholinergic drug, seeking for an alternative drug with less adverse effect or better storage effect. Accumulation of such experiences may further consolidate the findings of this pilot study. In summary, both tolterodine and obybutynin are effective for spina bifida patients and have comparable side effects, although an individualized approach is required for the choice of optimal drug because of the variable response of each case. Disclosure We do not have any conflict of interests with any company or institutes. REFERENCES 1. Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. JUrol1999; 162: de Jong TP, Chrzan R, Klijn AJ, Dik P. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol 2008; 23: Dik P, Klijn AJ, van Gool JD, de Jong-de Vos van Steenwijk CC, de Jong TP. Early start to therapy preserves kidney function in spina bifida patients. Eur Urol 2006; 49: Kanematsu A, Yamamoto S, Ogawa O. Changing concepts of bladder regeneration. Int J Urol 2007; 14: Kanofsky JA, Nitti VW. Tolterodine for treatment of overactive bladder. Urol Clin North Am 2006; 33: , viii. 6. Kreder KJ. Solifenacin. Urol Clin North Am 2006; 33: , ix. 7. Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008; 15: Ellsworth PI, Borgstein NG, Nijman RJ, Reddy PP. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. JUrol2005; 174: ; discussion Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006; 25:
5 Anticholinergics for Spina Bifida Patients Yucel S, Akkaya E, Guntekin E et al. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? Urology 2005; 65: Babu R. Effectiveness of tolterodine in nonneurogenic voiding dysfunction. Indian Pediatr 2006; 43: Reddy PP, Borgstein NG, Nijman RJ, Ellsworth PI. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol 2008; 4: Pontari MA, Braverman AS, Ruggieri MR Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004; 286: R Oka T, Nakano K, Kirimoto T, Matsuura N. Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats. Jpn J Pharmacol 2001; 87: Ferrara P, D Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int 2001; 87:
Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
More informationDepartment of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi , India
Original Article A Clinical and Urodynamic Study on the Effects of Oral Tolterodine on Serial Alterations in Neurogenic Detrusor Overactivity vis-à-vis Oral Oxybutynin in Children (Existing Oxybutynin
More informationLong-term persistence with mirabegron in a real-world clinical setting
International Journal of Urology (2018) 25, 501--506 doi: 10.1111/iju.13558 Original Article: Clinical Investigation Long-term persistence with in a real-world clinical setting Naoki Wada, Masaki Watanabe,
More informationNeurogenic Bladder. Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, Eric Levey, M.D.
Neurogenic Bladder Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, 2018 Eric Levey, M.D. Pediatrics & Neurodevelopmental Disabilities Chief Medical Officer,
More informationDepartment of Urology, Seoul National University Childrens' Hospital, Seoul National University College of Medicine, Seoul, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.12.828 Original Article Pediatric Urology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.12.828&domain=pdf&date_stamp=20141216 Efficacy,
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationCHAPTER 1 INTRODUCTION
Introduction 1 CHAPTER 1 INTRODUCTION 8 Introduction Spina bifida is a congenital defect of the spine in 1-3 out of 1000 live born children 1 and still is one of the most common serious congenital malformations.
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationUrodynamic study before and after radical porstatectomy 가톨릭의대성바오로병원김현우
Urodynamic study before and after radical porstatectomy 가톨릭의대성바오로병원김현우 Introduction Radical prostatectomy - treatment of choice for patients with localized prostate cancer. Urinary incontinence and/or
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationCase Based Urology Learning Program
Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 23 CBULP 2011 077 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,
More informationOkubo, Kazutoshi; Aoki, Katsuya; Wa. Right Research, Inc. Published by Elsevie
Title Objective patterning of uroflowmetr daytime and nighttime wetting. Kanematsu, Akihiro; Johnin, Kazuyos Author(s) Okubo, Kazutoshi; Aoki, Katsuya; Wa Yoshino, Kaoru; Tanaka, Shiro; Tani Osamu Citation
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More informationUrodynamic outcome of parasacral transcutaneous electrical neural stimulation for overactive bladder in children
ORIGINAL ARTICLE Vol. 41 (4): 739-743, July - August, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0303 Urodynamic outcome of parasacral transcutaneous electrical neural stimulation for overactive bladder in
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationEfficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
More informationClinical guidelines for overactive bladder
International Journal of Urology (2009) 16, 126 142 doi: 10.1111/j.1442-2042.2008.02177.x Guidelines Clinical guidelines for overactive bladder Osamu Yamaguchi, 1 Osamu Nishizawa, 2 Masayuki Takeda, 3
More informationRetrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder
European Urology European Urology 45 (2004) 240 244 Retrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder A. Raes a,, P. Hoebeke b, I. Segaert a, E. Van
More informationOveractive Bladder; OAB. Aδ silent C. Adenosine triphosphate; ATP SD g n Key words
25-32 2009 SD 200-270g n 28 4 1 2 3 4 PE-50 4-5 0.25 60 C Key words acupuncture stimulation overactive bladder rat bladder irritation C C fiber Received November 17, 2008; Accepted January 9, 2009 I Overactive
More informationRobotic Appendicovesicostomy
Robotic Appendicovesicostomy Cheryl Baxter, MSN,RN,CPNP Daniel DaJusta, MD Kristina Booth, MSN,RN,FNP Roadmap for Presentation Part 1 Pre-surgical/historical neurogenic bladder- Baxter Part 2 Robotic appendicovesicostomy/
More informationBrief Reports. Cystometric Evaluation of Voiding Dysfunctions
Brief Reports Cystometric Evaluation of Voiding Dysfunctions Pawanindra Lal Navneet Kaur Anurag Krishna Not infrequently, in pediatric practice one is confronted by anxious parents of children with voiding
More informationOveractive bladder can result from one or more of the following causes:
Overactive bladder can affect people of any age; however, it is more common in older people. Effective treatments are available and seeing your doctor for symptoms of overactive bladder often results in
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationAssociation of BPH with OAB: The Plumbing or the Pump?
Association of BPH with OAB: The Plumbing or the Pump? Ryan P. Terlecki, MD FACS Associate Professor of Urology Director, Men s Health Clinic Director, GURS Fellowship in Reconstructive Urology, Prosthetic
More informationCASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1
1 CASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1 35 years old man, who previously has been completely healthy, was shot twice in the neck
More informationAntimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?
Review Article SENSORY ACTIONS OF ANTIMUSCARINICS FINNEY et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? STEVEN M. FINNEY, KARL-ERIK
More informationNeuropathic Bladder. Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014
Neuropathic Bladder Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014 Plan Physiology- bladder and sphincter behaviour in neurological disease Clinical consequences of Symptoms
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationOveractive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
More informationOveractive bladder syndrome (OAB)
Service: Urology Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationAdult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline
Adult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline TARGET POPULATION Eligibility Decidable (Y or N) Inclusion
More informationDysfunctional Voiding Patients: When Do you Give Medication and Why (A Practical approach)
Dysfunctional Voiding Patients: When Do you Give Medication and Why (A Practical approach) Andrew Combs, PA-C Director, Pediatric Urodynamics Division of Pediatric Urology New York Presbyterian-Weill Cornell
More informationAccepted Manuscript. Does intraoperative success predict outcome in the treatment of urethral sphincter insufficiency with bulking agent?
Accepted Manuscript Does intraoperative success predict outcome in the treatment of urethral sphincter insufficiency with bulking agent? Niklas Pakkasjärvi, Seppo Taskinen PII: S1477-5131(18)30005-6 DOI:
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationJournal of Pharmacological Sciences
Journal of Pharmacological Sciences 128 (2015) 65e70 HOSTED BY Contents lists available at ScienceDirect Journal of Pharmacological Sciences journal homepage: www.elsevier.com/locate/jphs Full paper The
More informationEfficacy and Safety of Propiverine in Children with Overactive Bladder
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.275 Pediatric Urology Efficacy and Safety of Propiverine in Children with Overactive Bladder Woo Jung Kim, Dong-Gi Lee 1, Sang Wook Lee 2, Yoon
More informationUrodynamics in Neurological Lower Urinary Tract Dysfunction. Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne
Urodynamics in Neurological Lower Urinary Tract Dysfunction Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne Learning Objectives Review functional neurology relevant to lower
More informationDRUG FORECAST. Select Conditions of the Lower Urinary Tract
Transdermal Oxybutynin: Novel Drug Delivery for Overactive Bladder Vitalina Rozenfeld, PharmD, BCPS, Stanley Zaslau, MD, Kathleen New Geissel, PharmD, David Lucas, PhD, and Lili Babazadeh, PharmD INTRODUCTION
More informationOriginal Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:
Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION PROPIVERINE HYDROCHLORIDE (Mictoryl/Mictoryl Pediatric Duchesnay Inc.) Indication: Overactive bladder This document was originally issued on April
More informationPosterior Tibial Nerve Stimulation
Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)
More informationLuis Antonio Guerra,* David Moher, Margaret Sampson, Nicholas Barrowman, John Pike and Michael Leonard
Intravesical Oxybutynin for Children With Poorly Compliant Neurogenic Bladder: A Systematic Review Luis Antonio Guerra,* David Moher, Margaret Sampson, Nicholas Barrowman, John Pike and Michael Leonard
More informationHospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationPublic Assessment Report Scientific discussion. Oxybutynin Unimedic (oxybutynin hydrochloride) Asp no:
Public Assessment Report Scientific discussion Oxybutynin Unimedic (oxybutynin hydrochloride) Asp no: 2016-1468 This module reflects the scientific discussion for the approval of Oxybutynin Unimedic. The
More informationThe Effect ofverapamil on the Treatment of Detrusor Hyperreflexia in the Spinal Cord Injured Population
Paraplegia 27 (1989) 364-369 0031-1758/89/0027-0364$10.00 ([j 1989 International Medical Society of Paraplegia The Effect ofverapamil on the Treatment of Detrusor Hyperreflexia in the Spinal Cord Injured
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationSpinal dysraphism and neurogenic bladder: Still a relevant topic
The Journal of Medical Research 2017; 3(5): 234-238 Research Article JMR 2017; 3(5): 234-238 September- October ISSN: 2395-7565 2017, All rights reserved www.medicinearticle.com Received: 28-09-2017 Accepted:
More informationNishikawa et al. BMC Urology 2015, 15:2
Nishikawa et al. BMC Urology 2015, 15:2 RESEARCH ARTICLE Open Access Expression of parathyroid hormone/parathyroid hormone-related peptide receptor 1 in normal and diseased bladder detrusor muscles: a
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationThe new ICCS terminology J Urol 176, , 2006
The new ICCS terminology J Urol 176, 314-324, 2006 The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Report from the Standardisation Committee of the International
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationMuscarinic Receptor Binding of Imidafenacin in the Human Bladder Mucosa and Detrusor and Parotid Gland
LUTS (2011) 3, 64 68 ORIGINAL ARTICLE Muscarinic Receptor Binding of Imidafenacin in the Human Bladder Mucosa and Detrusor and Parotid Gland Masanao SEKI, 1 Masaki OGODA, 1 Shiori KURAOKA, 1 Atsushi OTSUKA,
More informationDetrusorectomy for neuropathic bladder in patients with spinal dysraphism
Detrusorectomy for neuropathic bladder in patients with spinal dysraphism Pieter Dik Georgo D. Tsachouridis Aart J. Klijn Cuno S.Uiterwaal Tom P.V.M. de Jong 4 published in J Urol. 2003 Oct;170(4 Pt 1):1351-4.
More informationOriginal Article. Annals of Rehabilitation Medicine INTRODUCTION
Original Article Ann Rehabil Med 2014;38(3):342-346 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.3.342 Annals of Rehabilitation Medicine Phasic Changes in Bladder Compliance
More informationOveractive Bladder in Clinical Practice
Overactive Bladder in Clinical Practice Alan J. Wein Christopher Chapple Overactive Bladder in Clinical Practice Authors Alan J. Wein Division of Urology University of Pennsylvania Health System Philadelphia
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More informationWhat is on the Horizon in Drug Therapy for OAB?
What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures
More informationDrugs for the overactive bladder: are there differences in persistence and compliance?
Editorial Drugs for the overactive bladder: are there differences in persistence and compliance? Karl-Erik Andersson 1,2 1 Institute for Regenerative Medicine, Wake Forest University School of Medicine,
More informationPhiladelphia College of Osteopathic Medicine. Victoria J. Kopec Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Treatment With OnabotulinumtoxinA
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationL ower urinary tract symptoms (LUTS) are a major health problem and are prevalent in men aged.45 years1 3.
OPEN SUBJECT AREAS: UROGENITAL DISEASES DRUG DEVELOPMENT Received 23 October 2013 Accepted 15 January 2014 Published 4 February 2014 Correspondence and requests for materials should be addressed to P.H.
More informationRelationship between Toe Temperature and Lower Urinary Tract Symptoms
LUTS (2012) 4, 144 149 ORIGINAL ARTICLE Relationship between Toe Temperature and Lower Urinary Tract Symptoms Hiroo INOUE, Osamu ISHIZUKA, Tetsuya IMAMURA, Takahiro YAMAGISHI, Wataru NOGUCHI, Hitoshi YOKOYAMA,
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationWho Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?
LUTS (2013) 5, 145 149 ORIGINAL ARTICLE Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign rostatic Hyperplasia? Jun OBATA, Kazuhiro
More informationNaoki Wada, Seiji Matsumoto, Masafumi Kita, Kazumi Hashizume and Hidehiro Kakizaki
bs_bs_banner International Journal of Urology (1) 1, 15 1 doi: 1.1111/iju.157 Original Article: Clinical Investigation Decreased urinary nerve growth factor reflects prostatic volume reduction and relief
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 4: , 2012
1112 Usefulness of total bladder capacity and post void residual urine volume as a predictor of detrusor overactivity with impaired contractility in stroke patients SANG HYUB LEE, JOONG GEUN LEE, GYEONG
More informationTreatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
652030TAU0010.1177/1756287216652030Therapeutic Advances in UrologyK. Kosilov et al. research-article2016 Therapeutic Advances in Urology Original Research Treatment compliance of working persons to high-dose
More informationComparative Study of Solifenecin Alone Versus Solifenecin with Duloxetine in Patients of Overactive Bladder
International Journal of Scientific and Research Publications, Volume 3, Issue 1, January 2013 1 Comparative Study of Solifenecin Alone Versus Solifenecin with Duloxetine in Patients of Overactive Bladder
More informationDisclosures. Background. Expanding the Xiao Concept to Spina Bifida
Lumbar to Sacral Nerve Rerouting to Restore Voiding and Bowel Function in Spina Bifida Kenneth M. Peters, MD Professor and Chairman of Urology Oakland University William Beaumont School of Medicine Royal
More informationImpact of urethral catheterization on uroflow during pressure-flow study
Research Report Impact of urethral catheterization on uroflow during pressure-flow study Journal of International Medical Research 2016, Vol. 44(5) 1034 1039! The Author(s) 2016 Reprints and permissions:
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationManagement of neurogenic bladder in children. In: Guidelines on paediatric urology.
Complete Summary GUIDELINE TITLE Management of neurogenic bladder in children. In: Guidelines on paediatric urology. BIBLIOGRAPHIC SOURCE(S) Management of neurogenic bladder in children. In: Tekgul S,
More informationSpina Bifida CIC booklet. A practical guide for nurses and health workers to do clean intermittent catheterization (CIC)
Spina Bifida CIC booklet A practical guide for nurses and health workers to do clean intermittent catheterization (CIC) International Federation for Spina Bifida and Hydrocephalus, 2012 Table of Contents
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationOAB Treatment Guidelines
OAB Treatment Guidelines This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. It is part of the activity Overcoming
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationVideo-urodynamics. P J R Shah Institute of Urology and UCH
Video-urodynamics P J R Shah Institute of Urology and UCH Bladder Function Storage Capacity and Pressure Emptying Pressure/flow/emptying URODYNAMIC INVESTIGATIONS Free urine flow rate Urethral pressure
More informationUrinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
More informationThe new International Continence Society
ROLE OF CYSTOMETRY IN EVALUATING PATIENTS WITH OVERACTIVE BLADDER ADAM J. FLISSER AND JERRY G. BLAIVAS ABSTRACT Overactive bladder (OAB) can be caused by a variety of conditions. We believe that cystometrography
More informationFlowmetry/ pelvic floor electromyographic findings in patients with detrusor overactivity
ORIGINAL ARTICLE Vol. 41 (3): 521-526, May - June, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0204 Flowmetry/ pelvic floor electromyographic findings in patients with detrusor overactivity Farshid Alizadeh
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationLong-Term Safety, Tolerability and Ef cacy of Extended-Release Tolterodine in the Treatment of Overactive Bladder
European Urology European Urology 41 (2002) 588±595 Long-Term Safety, Tolerability and Ef cacy of Extended-Release Tolterodine in the Treatment of Overactive Bladder K. Kreder a,*, C. Mayne b, U. Jonas
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationRecommandations de prise en charge des vessies neurogènes EAU 2006
Annexe 4-1 Recommandations de prise en charge des vessies neurogènes EAU 2006 (Version courte) 685 686 GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E.
More information